Charlene Banard, Former Global Head of Technical Operations Cell & Gene Therapy Strategy, Innovation Pipeline and PMONovartis
Jeffrey Berkowitz, Board MemberH. Lundbeck A/S
Ron Cohen, M.D., President & CEOAcorda Therapeutics
Lisa Conte, founder, president, and CEOJaguar Health
Laurie Cooke, former CEOHealthcare Businesswomen's Association (HBA)
John Crowley, Chairman and CEOAmicus Therapeutics
Rich Daly, Chief Operating OfficerBeyond Spring
Raúl Díaz, Animal Health Large Molecules Biopharm. OperationsMSD, Montes Claros, MG, Brazil
Tom Dilenge, President, Advocacy, Law & Public Policy DivisionBiotechnology Innovation Organization
Joseph Ferra, CFOElevation Oncology
Anu Hans, VP, Strategic InitiativesJanssen Supply Chain
Fred Hassan, Managing DirectorWarburg Pincus
Paul Hastings, President and CEONkarta Therapeutics
Axel Hoos, M.D., Ph.D., CEOScorpion Therapeutics
John Hubbard, Ph.D., Emeritus Editorial Advisory Board MemberLife Science Leader
Mitchell Katz, Ph.D., Vice President, Development OperationsFerring Pharmaceutical, Inc.
Mary Rose Keller, VP, Head Of Clinical OperationsAcrivon Therapeutics
Rachel King, CEOGlycoMimetics
Suresh Kumar, Former EVP External AffairsSanofi
John LaMattina, Ph.D., Sr. PartnerPureTech Health
Jacks Lee, SVP Global Manufacturing and SupplyMerck
Martin Lehr, CEOContext Therapeutics
Sandy Macrae, Ph.D., President & CEOSangamo Therapeutics
Ken Moch, Former President & CEOCognition Therapeutics
Carol Nacy, Ph.D., CEOSequella
Francois Nader, M.D., Chairman of the BoardAcceleron Pharma
Sandra E. Poole, Chief Operating OfficerMythic Therapeutics
Dennis Purcell, Founder & Sr. AdvisorAisling Capital
David Pyott, Chairman of the BoardBioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation CenterBayer
Stephen Rapundalo, Ph.D., President & CEOMichBio
Pamela Reilly Contag, Ph.D., Cofounder and CEOBioEclipse Therapeutics
John Reynders, Ph.D., VP, R&D Strategy, Program Management, and Data SciencesAlexion
James Robinson, Emeritus Editorial Advisory Board MemberLife Science Leader
Tomasz Sablinski, M.D., Ph.D., Managing Director, Head of Clinical DevelopmentAuven Therapeutics
Jim Scibetta, CEOImmuneID
Chhaya Shah, SVP Technical OperationsRadius Health
Allan Shaw, Independent Consultant
Brandi Simpson, VP Business and Corporate DevelopmentVoyager Therapeutics
Andrew Skibo, Emeritus Editorial Advisory Board Member, Life Science LeaderMedImmune / AstraZeneca
Jason Urban, Ph.D., Sr. Dir. Quality Risk ManagementAlexion
Thomas Wiggans, Founder, CEO, ChairmanDermira
Leslie Williams, Entrepreneur, Executive, Board Member, Mentor
Tim Wright, CEOMiMedx
ASK THE BOARD
- What Challenges Does Remote Work Present A Biopharma CEO?
- Where Do You Envision The Biopharmaceutical Industry In 2032 And Why?
- What Global Macro Trends Are You Paying Closest Attention To And Why?
- What Were Some Insights You Gained From Working As A Biopharma Manufacturing Exec During The Pandemic?
- How Did The Pandemic Impact You As An Executive?
- What Was The Biggest Insight You Gained From Working As A Biopharma Manufacturing Exec During The Pandemic?
IN THIS MONTH'S ISSUE
-
What To Expect From Cell Therapy And Gene Therapy In 2022 And Beyond12/1/2021
From innovations in clinical development and manufacturing to the evaluation of investigational cell and gene therapies (CGTs), subject matter experts from Cellectis and Immatics share a brief look back on 2021 and a detailed glimpse into the near future of gene therapy and cell therapy respectively.
-
Formulation Alternatives: Looking Beyond Parenteral Biologics12/1/2021
2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and efficacy hurdles, market forecasts are rising fast.
-
Can the FDA & CDC Recover from Recent Politics?12/1/2021
Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.
-
Is Janssen’s Pathway Approach The Future Of Drug Development12/1/2021
Two Janssen execs talk about the future of what they call a pathway approach to developing new medicines, which attempts to match the biology of a pathway to unmet medical need for patients, across a broad range of immune-mediated, inflammatory disease.
BEYOND THE PRINTED PAGE
@LIFESCILEADER1
EVENTS
-
Rare Disease Innovation and Partnering Summit
December 6 - 10, 2021
-
CMI International Microbiome Meeting (CIMM)
March 7 - 9, 2022
This website uses cookies to ensure you get the best experience on our website. Learn more